Beyond Weight Loss: Bioglutide™ in Alcohol Use Disorder & Combination Therapy

Updated: August 17, 2025 • Educational content only.

Biomed Industries is exploring Bioglutide™ (NA‑931) beyond obesity—into alcohol use disorder (AUD)—while also expanding protection with combination therapy patents.

Bioglutide in AUD: Preclinical Promise

  • Preclinical studies show NA‑931 attenuated alcohol-induced behaviors, such as alcohol-seeking and locomotor stimulation in animal models. [source]
  • Oral administration and favorable safety profile make it an intriguing candidate for AUD treatment.

Patents & Combination Therapy Strategy

  • Biomed filed patents for combining Bioglutide with semaglutide and tirzepatide. [source]
  • Preclinical data suggest enhanced weight loss and potential dose reduction in combination therapy.

Why This Matters

Diversifying Bioglutide’s applications could accelerate its value—including AUD therapy and synergistic effects with existing GLP-1 drugs.

FAQs

Is Bioglutide being tested in people with AUD?
Not yet—current data is preclinical. Clinical trials are required.

Does combination therapy increase risk?
Potentially—but lower dosing could mitigate side effects; safety evaluation is key in future trials.

Disclaimer

 This content is intended for informational and educational purposes only and is not intended to promote or sell any product. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new supplement or research compound. The statements provided have not been evaluated by the FDA or Health Canada and are subject to change as scientific understanding evolves.

Back to blog